Evelo Biosciences(US:EVLO)2020-03-05 12:22Company Overview and Strategy - Evelo is developing oral biologics targeting SINTAX for favorable safety and efficacy profiles[5] - The company aims to create a new market as a mid-line therapy, potentially deferring the use of biologics and specialty drugs[9] - Evelo's strategy involves serving individuals across all stages of diseases globally in the long term[9] EDP1815 Clinical Development - Interim Phase 1b clinical data for EDP1815 shows an attractive profile in psoriasis and broad potential in treating inflammatory disease[6] - In a Phase 1b trial, a mean PASI reduction of 21% was observed at day 42 at the high dose compared to a 3% reduction in the placebo group[21] - 50% of individuals dosed with EDP1815 achieved at least PASI 25 at Day 42 vs 10% with placebo[22] - A Phase 2 trial for EDP1815 in psoriasis is planned for initiation in 2Q 2020, with interim data expected in late 2020[7, 26] Pipeline and Platform - Evelo's platform discovers and develops oral biologics targeting SINTAX, modulating clinically validated cytokines[12] - EDP1503, in collaboration with Merck, is undergoing Phase 1/2 trials in MSS Colorectal Cancer, Triple-negative Breast Cancer, and Anti-PD-1 Relapsed responders[7, 18] - The company had approximately $77.8 million in cash and cash equivalents as of December 31, 2019[42]